BM-R16

BM-R16 is an investigational drug candidate being developed by Bainei Pharmaceutical (also known as Beimei Pharma) for the treatment of atopic dermatitis (AD). As of 2024, the agent is in Phase 1 clinical development, specifically undergoing a pilot study to evaluate its safety and efficacy in patients with AD. BM-R16 is part of the company's 'R' series pipeline, which typically focuses on 'Class 2' improved new drugs in China—a category that includes new formulations, new delivery systems, or new indications for known active ingredients. While the specific mechanism of action, molecular target, and chemical composition have not been publicly disclosed, the drug is being developed as part of Beimei's specialized portfolio in dermatology and inflammatory diseases.